Insights

More Articles Back to Article

Regulatory Utilization of Real-World Data and Real-World Evidence in Japan: Pharmaceuticals and Medical Devices Agency (PMDA) Chief Executive Perspective

In cases when a randomized controlled trial cannot be conducted because of the limited patient population for rare diseases or other reasons, the PMDA has been making good use of RWD/RWE for regulatory decision-making.